Are you a financial expert?Login
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Signup

DRREDDY Consensus Forecast

No. of reports in last year
15
No. of analysts
7
Average Consensus Forecast
3452.8
Consensus Potential
-33.66%

DRREDDY Price Target Potential

BrokerageTargetPotential
Prabhudas Lilladher4326-4.51%
Nirmal Bang3647-23.97%
ICICIdirect.com46152.04%
Karvy Stock Broking3378-33.84%
HDFC Securities3440-31.43%

DRREDDY Targets in FrontPage Forums

1 Users have submitted 1 trade ideas of Rs. 3,675.75 for DRREDDY
100% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

DRREDDY Ratings

Long term DRREDDY rating by FrontPage users
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
4.5/5 (11 Ratings)
15 DRREDDY share price target reports by brokerages below. See what is analyst's view on DRREDDY share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. DRREDDY Forum
  3. DRREDDY Price Target

DRREDDY Share Price Target

DRREDDY Share Price Target - Broker Reports - 2020

29-Jul-20
Price @ Call: 4231.35
Target: 4326
HOLD
21-May-20
Price @ Call: 3873.92
Target: 3647
SELL
DRL’s earnings performance is expected to improve going forward and will be led by growth across geographies. North America can grow in high single digit to midteens, depending on the timing and quality of approvals. The company also continues to leverage its US portfolio for a global roll out – Emerging Markets, China and Europe, which should help it to sustain growth in these geographies. India and PSAI businesses are poised in a favourable demand environment and should continue to grow. India can grow in low teens on an organic basis. Integration of Wockhardt portfolio should add to the growth. We value DRL at 20x FY22 EPS and assign a target price of Rs3,647, which represents a downside of 7% from the CMP. We retain Sell rating on the stock given the rich valuation it is trading at.
... Read more
21-May-20
Price @ Call: 3910.75
Target: 4615
BUY
Notwithstanding Q4 related positive/negative gyrations, overall narrative of calibrated launches and focus on sustained cost rationalisation, especially on SGN&A front and R&D spend continues. We expect continuum in operational improvement due to strong growth from branded markets, control on overheads and reduction in regulatory spend, now that most facilities including Srikakulam API plant (VAI) are out of USFDA embargo. We draw comfort from the management commentary, especially their endeavour to focus on simultaneous launches across geographies and segments besides continued efforts towards controlling SG&A expenses. We believe this is a welcome change from the earlier stance of overemphasis on a particular market (read US). Strong FCF generation and healthy balance sheet are some legacy strongholds for the company. Despite the recent rally, the expected margin expansion and earnings upgrade still leave scope for upside. We upgrade from HOLD to BUY and arrive at a target price of Rs 4615 based on 22x FY22E EPS of ~Rs 209.7.
... Read more
21-May-20
Price @ Call: 3910.75
Target: 4326
ACCUMULATE
We continue to believe that DRRD is one of the best play in large-cap pharma space a) due to its control on overhead expenses, b) focus on domestic business, c) injectable pipeline for US and EU, d) net cash on books and e) resolution for all major FDA issues. Over FY21-22E, DRRD will likely see change is business mix with high margin domestic formulation (17% of revenue FY20) contributing more to the revenue. DRRD had already recognized (even earlier than its peers) about challenging environment in the US market and accordingly reduced capital allocation. In Q4FY20, US-Gx growth was mainly due to stock up which helped to net-off muted performance of other regions. This trend seems unlikely in future as US-Gx has already normalized as per management guidance. We expect normalized growth in India formulations however EU and EMs to be major growth drivers to refill the lower growth in US-Gx and Russia for 1HFY21E. We change our earnings estimate marginally and continue to assign 24x PE on FY22E and arrive at new TP Rs4326(Rs4030). We maintain ‘Accumulate’ rating
... Read more
29-Jan-20
Price @ Call: 3159.02
Target: 3255
HOLD
Excluding impairment charges, the Q3 result was better than I-direct estimates on all fronts with healthy growth across geographies and strongest operational (adjusted for impairment) margins in the past 20 quarters. Sustained cost rationalisation, especially on the SGN&A front and calibrating of R&D spend are some continuing hallmarks. Despite recent product related setbacks in the US, the company remains focused on the US market but will be calculative and plans to push only those products with better EBITDA profile. We expect a continuum in operational improvement due to strong growth from branded markets, control on overheads and reduction in regulatory spend. Overall, it is still a work in progress for the company with product/segment identification for growth and cost rationalisation drive likely to continue for the next few quarters. We arrive at our target price of Rs 3255 based on 18x FY22E EPS of ~| 180.9.
... Read more
29-Jan-20
Price @ Call: 3188.8
Target: 3378
HOLD
We downgrade our Revenues by 0.6% for FY20E due to lower US revenues while we upgrade by 0.9% for FY 21E due to better traction in US, EU and India business. We upgrade our EBITDAM by 270 bps to 25.5% for FY20E due to better gross margins, lower SGA and R & D expenses. We marginally downgrade our EBIDTAM by 50 bps for FY 21E. We downgrade our EPS estimates by 33.5% to Rs. 101.3 mainly on account of Impairment charge. We upgrade our EPS estimates for FY21E by 1.1% to Rs. 157.1. We revise our price target to Rs. 3,378 based on 21.5x FY21E and downgrade our rating to HOLD.
... Read more
29-Jan-20
Price @ Call: 3188.8
Target: 3440
NEUTRAL
We resume coverage on Dr Reddy’s with a Neutral rating and a TP of Rs 3,440 based on 20x FY22 EPS. With improved performance across geographies we believe the multiple is well justified. While DRL has a rich pipeline of products for the US market, approval and launch timeline for key products - gNuvaring and gCopaxone does remain elusive. Despite factoring in these launches along with sustenance of good performance in non US markets and margin expansion as per company outlook, upside is limited from current market price.
... Read more
28-Jan-20
Price @ Call: 3188.95
Target: 3331
ACCUMULATE
Overall core sales, adj. EBITDA and adj. PAT were above our estimates due to geography mix, better product mix and operating leverage. DRRD sales, EBITDA and adj. PAT grew 8%, 27%, and 4% QoQ. EBITDA margin expanded by 263bps YoY and 356bps QoQ to 23.5%. Adj.PAT was higher on account of a lower tax of 4% due to benefits from new tax regime. Global Generics grew 15% YoY on account of growth across all regions (North America 8%, Europe 52%, India 13%, EM 13%). With delay in approval of gNuvaring, DRRD provisioned impairment charges of Rs11.1b in Q3FY20, while an additional Rs2.1bn charge was taken related to impairment of other IP assets. Staff costs, SGA, and R&D increased by 1.5%, 5%, and 7.8% QoQ respectively. With increase in earnings contributed by US, India, and Russia, we assign PE 20x on FY22E earnings and derive new TP of Rs3,331, increase by 14% over our previous TP of Rs2,910 to reflect the teething problems in individual products manufacturing issues with FDA. We maintain our recommendation ‘Accumulate’. Further erosion in US generics, delay in launches, and delay in FDA resolution could be an overhang on DRRD.
... Read more

DRREDDY Share Price Target - Broker Reports - 2019

12-Nov-19
Price @ Call: 2813.27
Target: 2961
HOLD
We expect earnings to grow at healthy 12% CAGR over FY19-21E. We assign HOLD rating on the stock with a target price of Rs. 2,961 using a target multiple of 20x P/E on FY21E adj. EPS.
... Read more
5-Nov-19
Price @ Call: 2824.24
Target: 3259
BUY
Dr. Reddys Lab’s (DRL) revenue, increased by 26.4% YoY to Rs 48bn, is higher than our estimates of Rs43.3 bn, primarily due to good growth in Domestic, Europe and Emerging market and licence fees for three proprietary products. EBITDA margins were at 22.2% higher than our estimates of 20.2% on account of robust revenue and better gross margin. Net profit increased by 116.9% to Rs 10,925 mn (higher than our estimate of Rs 4,801 mn in Q2FY20).
... Read more
4-Nov-19
Price @ Call: 2754.55
Target: 3188
BUY
We recommend buy rating on the stock with a new target price of Rs3,188 (from Rs3,138 earlier) which is based on 18x P/E to the base business (September FY21E EPS) with RS 50 per share risk adjusted value for the proprietary pipeline. DRL revenue and net profit should be on a secular growth trajectory as all business segments are well poised to grow. The worst around the US business is behind and it can grow in mid-to-high single digit on the current base (adjusted for base business erosion). The recent launches in the US, which are yet to scale up, can add about US$100mn to existing revenue base on an annual basis by mid FY21. The pace of erosion in DRL’s US revenue can be higher than average for the industry due to a large number of incremental launches being limited competition in nature.
... Read more
1-Nov-19
Price @ Call: 2783.58
Target: 2910
BUY
Maintain ‘Accumulate’, TP marginally decrease to Rs2,910: With traction in India form ulations and revam ped portfolio of US generics along with visibility of launches of key products will bring qualitative improvement in earnings estimates.PriceerosioninUSduetochannelconsolidationhasbeen gradually stable for its portfolio of generics. The better visibility of launching gNuvaring and gCopaxone in FY21E will make its risk-return ratio favourable. We assign PE 21x on FY22E earnings and derive new TP of Rs2,910, decrease by 2% over our previous TP of Rs2,997 to reflect the teething problems in individual products. We maintain our recommendation ‘Accumulate’.
... Read more
22-Oct-19
Price @ Call: 2781.03
Target: 2997
ACCUMULATE
Teva’s settled with multiple litigants in opioid epidemic cases in US. A major part of the deal is long term (3 and 10 years) supply gSuboxone tablets to various state and local govt bodies. We expect the Teva supply to be utilized in the govt program of Medicare and Medicaid. Besides, a lower priced tablet would hardly encourage patient shift from sublingual films (easy operability). Unless patients are forced shift to tablet forms (through changes in formularies), there will be hardly any meaningful impact in volumes for film market. Hence DRRD, being second highest Rx share, is unlikely to be impacted from the Teva deal due to a)lower probability of patient/volume shift and b)lower competition to increase Rx share post Sandoz exit. We maintain‘Accumulate’ recommendation and retain TP at Rs2,997.
... Read more
11-Oct-19
Price @ Call: 2637.35
Target: 2900
BUY
25-Sep-19
Price @ Call: 2784.6
Target: 3259
BUY
30-Jul-19
Price @ Call: 2625.49
Target: 2840
HOLD
Revenues were driven by strong growth in India, Europe and RoW markets. After weeding out one-offs, exceptional items, postponements etc, the current narrative of the company remains intact- 1) focus on few remunerative products and 2) control over cost and capital. The management remains committed to working on cost rationalisation, especially on the SGN&A front and calibrating of R&D spend more towards global generics front (30+ US launches targeted in FY20) and biosimilars and lower towards proprietary products. We expect EBITDA margins to improve in FY19-21 due to key launches in the US, control on overheads and likely reduction in the regulatory spend. Overall, it is still a work in progress for the company with product/segment identification for growth and cost rationalisation drive likely to continue for the next few quarters. We arrive at our new target price of Rs 2840 based on 18x FY21E EPS of ~Rs 157.7.
... Read more
2-Aug-19
Price @ Call: 2522.57
Target: 3281
BUY
Gross margin for the quarter stood at 51.7%, which was down 70bps QoQ, however after adjusting last quarter for one time income on sale of derma brand s there is an increase of 150bps in margin. Gross margins of global generic business which stood at 57.6% was also adversely impacted 80bps due to inventory related provisions. Earnings stood at Rs6,628mn during the quarter, which showed 45.3% growth YoY and was boosted by exceptional gains from settlement income of $50mn. We have retained Buy rating on the stock with a target price of Rs3281 at 18x March FY21E EPS.
... Read more
31-Jul-19
Price @ Call: 2562.05
Target: 3360
BUY
Having overcome regulatory issues at key formulations plants, the co is rapidly ramping up US revenues with key oncology and injectables launches. Additionally, biosimilar and complex generics launches in EM and reg markets, renewed focus on India, and traction gained in EU & China will support rev CAGR of ~15% over FY19-21E. We maintain BUY on DRRD following a miss on our estimates driven by temporary issues. Our TP is unchanged at Rs 3,360 (20x FY21E EPS + Rs 380/sh for niche products). A visible ramp up in the US and further cost efficiencies enable us to stay confident.
... Read more
30-Jul-19
Price @ Call: 2652.55
Target: 2997
ACCUMULATE
Upgrade to ‘Accumulate’, increase TP to Rs2,997: With traction in India formulations and revamped portfolio of US generics along with visibility of launches of key products will bring qualitative improvement in earnings estimates. Price erosion in US due to channel consolidation has been gradually stable for its portfolio of generics. The better visibility of launching gNuvaring and gCopaxone in CY19E-20E will make its risk-return ratio favourable. We assign PE 18x on FY21E earnings and derive new TP of Rs2,997, improved by 17% over our previous TP of Rs2,558. We upgrade our recommendation to ‘Accumulate’.
... Read more
14-Jun-19
Price @ Call: 2556.47
Target: 2880
BUY
We marginally cut our earnings estimates by 8%/2% for FY20E/FY21E, taking into account the delay in the approval of key high value products like gCopaxone (in H1FY21 vs. H2CY19 earlier) and gNuvaring (in H2FY20 vs H1CY19). We value DRRD at 20x on FY21E earnings, with Buy rating and target price of Rs 2,880. Key risk to our call would be further delay in approval of key assets (gNuvaring and gCopaxone), regulatory hurdles and higher- than-expected pricing pressure in the base portfolio.
... Read more
14-Jun-19
Price @ Call: 2586.15
Target: 3400
BUY
Exciting times ahead; reiterate ‘BUY’
With focused management, promising complex pipeline, strong earnings revival and compelling valuations, DRRD remains a strong growth story over FY20–21. We reiterate‘BUY/SP’ with TP of INR3,400. The stock is trading at 17.3x FY20E earnings.
... Read more
13-Jun-19
Price @ Call: 2590.9
Target: 3281
BUY
21-May-19
Price @ Call: 2588.05
Target: 3122
HOLD
We downgrade our Revenues for FY20E by 1% while we upgrade by 1.2% for FY 21E. We downgrade EBITDAM by 50 bps for FY20E while we maintain our FY21E at 21.8 % mainly on account of higher R & D. We upgrade our EPS estimates for FY20E by 9.5% to Rs 135.8 mainly due to Celegene settlement income being factored in FY20E while we upgrade by 2.1% to Rs 144.9 for FY 21E. We maintain our price target at Rs 3122 based on 21.5x FY21E and maintain our HOLD rating on the stock.
... Read more
19-May-19
Price @ Call: 2754.41
Target: 2997
HOLD
The management is revamping organizational structure to make it more mobile, faster and opportunistic for cashing strategic opportunities. While there will be delay to launch gNuvaring and gCopaxone, the EIR for Duvvada plant and likely resolution of Vizag plant (TRO) will release approvals of key injectables in FY20E-21E. India formulations are also guided to increase operating efficiency of sales force, a key parameter DRRD is lagging vis-à-vis peers for long time. We increased earnings by 14% and 22% in FY20E and FY21E, though assigning PE 18x of FY21E (for new TP of Rs2,997 from Rs2,558) due to requirement of better visibility. We expect PEx to be rerated with approvals and upcoming launch of undisclosed key products as guided by DRRD. We upgraded our recommendation to ‘Hold’.
... Read more
19-Feb-19
Price @ Call: 2570
Target: 2950
BUY
DRRD reported in-line numbers with revenues of Rs 3850 crs (vs estimate of Rs3867crs), EBITDA Rs816crs (vs estimate of Rs 770 crs) and PAT Rs478crs (estimate Rs401crs). Healthy operating performance was led by (a) Steady revenue growth in the domestic formulation business (up 10% YoY), (b) Strong margins in PSAI segment on QoQ and YoY basis, and (c) robust revenue growth in emerging markets like Russia (up 21% YoY) and Other CIS region (up 40% YoY). North America business remained muted due to high price erosion in some of the key molecules. Sequentially, North America business exhibited growth of ~4%, led by volume uptake and new launches. We have a Buy rating on the stock, with a Target price of Rs. 2,950, valuing DRRD at 20x PE on FY21 earnings of Rs148. The key risk would be delay in clearance of Srikakulam facility, delay in approval of niche products (like gNuvaring and gCopaxone) and higher-than-expected pricing pressure in the key products.
... Read more
18-Feb-19
Price @ Call: 2435.26
Target: 3450
BUY
6-Feb-19
Price @ Call: 2810.1
Target: 3260
BUY
6-Feb-19
Price @ Call: 2810.1
Target: 2558
REDUCE
4-Feb-19
Price @ Call: 2800.74
Target: 2870
HOLD
14-Jan-19
Price @ Call: 2581.31
Target: 2974
BUY

DRREDDY Share Price Target - Broker Reports - 2018

27-Nov-18
Price @ Call: 2574.03
Target: 3350
BUY
30-Oct-18
Price @ Call: 2520.19
Target: 2952
BUY
29-Oct-18
Price @ Call: 2534.75
Target: 2700
BUY
26-Oct-18
Price @ Call: 2406.76
Target: 2170
REDUCE
30-Jul-18
Price @ Call: 2070.58
Target: 2200
HOLD
27-Jul-18
Price @ Call: 2090.42
Target: 1950
REDUCE
27-Jul-18
Price @ Call: 2090.42
Target: 2170
HOLD
27-Jul-18
Price @ Call: 2134.65
Target: 3350
BUY
27-Jul-18
Price @ Call: 2134.65
Target: 2170
NEUTRAL
27-Jul-18
Price @ Call: 2134.65
Target: 1766
REDUCE
23-Jul-18
Price @ Call: 2049.08
Target: 2898
BUY
4-Jul-18
Price @ Call: 2274.5
Target: 2730
BUY
29-Jun-18
Price @ Call: 2274.2
Target: 3350
BUY
26-Jun-18
Price @ Call: 2290.1
Target: 1766
REDUCE
16-Jun-18
Price @ Call: 2352.67
Target: 1766
REDUCE
23-May-18
Price @ Call: 1965.6
Target: 3350
BUY
23-May-18
Price @ Call: 1960.12
Target: 2000
NEUTRAL
23-May-18
Price @ Call: 1960.12
Target: 1766
REDUCE
21-Mar-18
Price @ Call: 2157.4
Target: 2378
ADD
29-Jan-18
Price @ Call: 2392.43
Target: 3450
BUY
25-Jan-18
Price @ Call: 2522.95
Target: 2575
NEUTRAL
26-Jan-18
Price @ Call: 2522.95
Target: 2703
ACCUMULATE

DRREDDY Share Price Target - Broker Reports - 2017

15-Dec-17
Price @ Call: 2313.7
Target: 2400
HOLD
28-Nov-17
Price @ Call: 2297
Target: 2075
REDUCE
24-Nov-17
Price @ Call: 2309.63
Target: 2040
REDUCE
13-Nov-17
Price @ Call: 2351.21
Target: 3450
BUY
2-Nov-17
Price @ Call: 2360.9
Target: 2520
HOLD
1-Nov-17
Price @ Call: 2431.4
Target: 2575
BUY
21-Sep-17
Price @ Call: 2313.6
Target: 3500
BUY
11-Sep-17
Price @ Call: 2158.8
Target: 2400
NEUTRAL
2-Sep-17
Price @ Call: 2187.02
Target: 2500
HOLD
28-Aug-17
Price @ Call: 2087.9
Target: 3050
HOLD
28-Jul-17
Price @ Call: 2621
Target: 2275
SELL
28-Jul-17
Price @ Call: 2478
Target: 2523
HOLD
28-Jul-17
Price @ Call: 2474.68
Target: 2599
HOLD
29-Jun-17
Price @ Call: 2655.5
Target: 3366
BUY
15-May-17
Price @ Call: 2667
Target: 2926
BUY
12-May-17
Price @ Call: 2581
Target: 2600
HOLD
9-Mar-17
Price @ Call: 2715
Target: 3050
NEUTRAL
27-Feb-17
Price @ Call: 2910
Target: 2600
SELL
10-Feb-17
Price @ Call: 2992.04
Target: 2700
SELL
3-Feb-17
Price @ Call: 3129.34
Target: 3020
SELL
6-Feb-17
Price @ Call: 3145
Target: 3325
NEUTRAL
6-Feb-17
Price @ Call: 3095
Target: 3523
BUY
6-Feb-17
Price @ Call: 3090
Target: 3224
NEUTRAL

DRREDDY Share Price Target - Broker Reports - 2016

26-Oct-16
Price @ Call: 3201
Target: 3370
HOLD
26-Oct-16
Price @ Call: 3200.45
Target: 3523
ACCUMULATE
27-Jul-16
Price @ Call: 3013
Target: 2800
SELL
27-Jul-16
Price @ Call: 3016.05
Target: 3950
BUY
27-Jun-16
Price @ Call: 3246.6
Target: 3280
HOLD
15-Jun-16
Price @ Call: 3087.7
Target: 3200
NEUTRAL
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
Join FrontPage

  • DRREDDY Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 34,801.63
    Upside Target 24,735.82
    Upside Target 14,631.63
    Pivot4,565.82
    Downside Target 14,461.63
    Downside Target 24,395.82
    Downside Target 34,291.63

  • DRREDDY Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 35,330.1
    Upside Target 24,945.05
    Upside Target 14,733.05
    Pivot4,348
    Downside Target 14,136
    Downside Target 23,750.95
    Downside Target 33,538.95

  • DRREDDY Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 35,528.7
    Upside Target 25,044.35
    Upside Target 14,782.7
    Pivot4,298.35
    Downside Target 14,036.7
    Downside Target 23,552.35
    Downside Target 33,290.7

  • DRREDDY Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 34,735.82
    Upside Target 24,670.88
    Upside Target 14,630.76
    Pivot4,565.82
    Downside Target 14,500.88
    Downside Target 24,460.76
    Downside Target 34,395.82

  • DRREDDY Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 34,945.05
    Upside Target 24,716.98
    Upside Target 14,576.07
    Pivot4,348
    Downside Target 14,119.93
    Downside Target 23,979.02
    Downside Target 33,750.95

  • DRREDDY Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 35,044.35
    Upside Target 24,759.38
    Upside Target 14,583.32
    Pivot4,298.35
    Downside Target 14,013.38
    Downside Target 23,837.32
    Downside Target 33,552.35
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
Privacy•Terms•••
FrontPage © 2020